Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will announce its earnings results before the market opens on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The company had revenue of $23.57 million during the quarter, compared to the consensus estimate of $24.64 million. During the same quarter in the prior year, the firm earned ($0.31) earnings per share. The firm’s revenue was down 10.8% compared to the same quarter last year. On average, analysts expect Momenta Pharmaceuticals to post $-0.75 EPS for the current fiscal year and $-1.08 EPS for the next fiscal year.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at 14.50 on Monday. The company’s market cap is $1.07 billion. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.75 and a 12 month high of $19.90. The stock’s 50 day moving average is $15.61 and its 200 day moving average is $15.81.
A number of research analysts recently issued reports on MNTA shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They set a “neutral” rating and a $18.00 target price on the stock. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Robert W. Baird downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their target price for the company from $22.00 to $15.00 in a research report on Friday, October 6th. Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $15.00 target price (down previously from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $15.00.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 35,667 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares in the company, valued at approximately $5,444,882.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the business’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the sale, the president now owns 269,231 shares of the company’s stock, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. Insiders have sold a total of 79,663 shares of company stock valued at $1,414,498 in the last 90 days. 4.40% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Scheduled to Post Quarterly Earnings on Tuesday” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/10/30/momenta-pharmaceuticals-inc-mnta-scheduled-to-post-quarterly-earnings-on-tuesday.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
What are top analysts saying about Momenta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Momenta Pharmaceuticals Inc. and related companies.